We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look ...

Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company ...

StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) said its Board has authorized a new share repurchase program under which Neurocrine may repurchase up to $500 million of its shares. The new share ...

In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other fast growth stocks to buy right now. In the fourth quarter of 2024 ...